Q-omics provides the consensus-scored ZNF326 profile across patient tissues and cancer cell-line models. ZNF326 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF326 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, ZNF326 protein abundance shows 28,344 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KICH, and LSCC as cancer lineages where ZNF326 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF326 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF326 survival associations across molecular data types. ZNF326 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF326 RNA expression–survival associations across cancer types. High ZNF326 expression shows unfavorable associations in ACC, LGG and KICH, but favorable associations in SCLC, READ and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF326 RNA expression.
This table summarizes ZNF326 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF326. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF326 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in STAD, LUSC and BLCA. The KICH box plot shows higher ZNF326 RNA expression in normal versus tumor tissue (log2 FC = −1.170, t-test p < 0.001).
This table shows molecular features associated with ZNF326 in patient tissues and cancer cell lines. In patient samples, ZNF326 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF326 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
